Pexidartinib vs. Vimseltinib for TGCT: Which Is Right?

For adults with symptomatic tenosynovial giant cell tumor (TGCT) that causes severe functional limitations and cannot be improved with surgery, pexidartinib (Turalio) and vimseltinib represent the two major targeted systemic therapies ^[1][2]. Both drugs have been shown to shrink tumors and improve symptoms for a portion of patients ^[3][4].

Because these medications have very different safety profiles, dosing schedules, and monitoring requirements, choosing between them is a highly individualized decision made with a multidisciplinary medical team.

At a Glance: Pexidartinib vs. Vimseltinib

How They Work

Both medications belong to a class of drugs called CSF1R inhibitors. In TGCT, tumor cells overproduce a signal (CSF1) that recruits large numbers of inflammatory cells to the joint, causing tissue damage and tumor growth ^[8].

• Pexidartinib blocks the CSF1R receptor, cutting off this inflammatory signal. However, it also blocks other receptors in the body, which contributes to its side effects ^[1].
• Vimseltinib is a newer medication designed to be more selective, meaning it targets the CSF1R receptor with less impact on other pathways ^[9].

Efficacy: What the Trial Numbers Mean

Both drugs were evaluated in separate, major clinical trials (ENLIVEN for pexidartinib, MOTION for vimseltinib) against a placebo. At 25 weeks of treatment:

• 39% of patients taking pexidartinib saw significant tumor shrinkage ^[3].
• 40% of patients taking vimseltinib saw significant tumor shrinkage ^[4].
• In both trials, 0% of patients on the placebo saw similar tumor shrinkage ^[3][4].

Understanding these numbers: An objective response rate of around 40% means that about 4 in 10 patients met a strict, predefined threshold for tumor shrinkage on an MRI. It does not mean the drugs cure the condition or work for everyone. Furthermore, because these were completely separate trials and not a head-to-head comparison, these numbers cannot be used to claim one drug works better than the other ^[3][4]. Patients in both trials also reported clinically meaningful improvements in joint pain and stiffness ^[3][4].

Side Effects and Safety Profiles

The most important distinction between these two medications is their side effects.

Pexidartinib and Liver Risk

Pexidartinib carries a “boxed warning”—the strictest safety warning—for severe and potentially fatal liver injury ^[6]. In clinical trials, some patients developed serious liver toxicity ^[3][10].

Because of this risk, pexidartinib is only available through a restricted safety program called a REMS (Risk Evaluation and Mitigation Strategy) ^[6]. You must enroll in this program and undergo frequent, mandatory liver blood tests.

• Warning Signs: Contact your doctor immediately if you develop yellowing of your skin or the whites of your eyes (jaundice), dark “tea-colored” urine, pale stools, severe nausea, unusual tiredness, or pain in the upper right side of your stomach.
• Other common side effects include changes in hair color, fatigue, rash, and nausea ^[3].

Vimseltinib and New Side Effects

While vimseltinib was developed to be more selective, it still requires safety monitoring. In its main trial, there was no evidence of severe drug-induced liver injury, but it can still cause abnormal liver enzyme tests, meaning regular blood monitoring is still necessary ^[4].

Vimseltinib also has distinct side effects:

• Fluid Retention: It can cause swelling, notably periorbital edema (swelling around the eyes) ^[4]. Contact your team for rapid weight gain, severe swelling, or shortness of breath.
• Muscle Enzyme Elevations: About 10% of trial patients experienced severe elevations in a muscle enzyme called creatine phosphokinase (CPK) ^[4]. Contact your doctor if you have severe, unexplained muscle pain, weakness, or dark urine.

Reproductive Safety

Both pexidartinib and vimseltinib are systemic therapies that can cause serious harm to an unborn baby ^[1][2]. If you or your partner can become pregnant, you must use highly effective contraception during treatment and for a specified period after your last dose. Discuss pregnancy plans, contraception, and breastfeeding with your doctor before starting.

Dosing and Daily Life

The daily routine for these medications differs significantly:

• Pexidartinib: Taken twice a day. Crucially, each dose must be taken with a low-fat meal containing approximately 11 to 14 grams of fat ^[5]. If the meal has too much or too little fat, your body may absorb the wrong amount of the drug, which can be dangerous.
• Vimseltinib: Taken just twice a week. The doses must be separated by 3 to 4 days (for example, taking it every Tuesday and Friday) to ensure safe drug levels in your body ^[4].

Medication Interactions

Both drugs interact heavily with enzyme pathways in the liver (specifically the CYP3A pathway) ^[11]. Mixing them with certain medications can cause the TGCT drug levels in your blood to drop (making it ineffective) or spike (increasing toxic side effects).

• Do not start or stop any medication without asking your doctor.
• Have a clinical pharmacist review your entire list of prescription drugs, over-the-counter medicines, herbal supplements, and antacids before starting either treatment.

How Doctors Choose

When deciding between pexidartinib and vimseltinib, your specialist will individualize the choice based on:

1. Your Baseline Liver Health: Pre-existing liver conditions heavily influence the safety of pexidartinib.
2. Monitoring Capability: Your ability to frequently travel to a clinic for REMS-mandated blood draws ^[6].
3. Other Health Issues: A history of severe fluid retention, kidney disease, or eye issues might make vimseltinib less ideal.
4. Lifestyle and Diet: Your ability to strictly manage a low-fat diet twice daily versus taking a pill twice a week ^[5][4].